Evidence mapPaperPMID 39331145Full record

ReviewHerzschrittmachertherapie & Elektrophysiologie2024

[Atrial fibrillation in combination with severe mitral regurgitation : Which should be treated first, the atrial fibrillation or the mitral valve?]

Nora Köpcke, Fabian Barbieri, Mario Kasner, Markus Reinthaler, Ulf Landmesser, Martin Huemer, Philipp Attanasio

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Herzschrittmachertherapie & Elektrophysiologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nora KöpckeKlinik für Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203, Berlin, Deutschland. nora.koepcke@dhzc-charite.de.
Fabian BarbieriKlinik für Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203, Berlin, Deutschland.
Mario KasnerKlinik für Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203, Berlin, Deutschland.
Markus ReinthalerKlinik für Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203, Berlin, Deutschland.
Ulf LandmesserKlinik für Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203, Berlin, Deutschland.
Martin HuemerKlinik für Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203, Berlin, Deutschland.
Philipp AttanasioKlinik für Kardiologie, Angiologie und Intensivmedizin, Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe primary therapeutic approach for severe secondary mitral regurgitation (MR) in combination with atrial fibrillation is often not clear. OBJECTIVES/

methodsTo create a therapeutic guideline for daily clinical practice based on a case report as well as basic literature.

resultsIf a functional component is suspected, restoration of sinus rhythm may lead to a significant improvement in MR. The extent of the improvement and the time required to achieve this improvement are often difficult to predict.

conclusionsThe involvement of an electrophysiologist is recommended in order to assess the likelihood of successful long-term rhythm control aimed at improving MR. In unclear cases, cardioversion combined with short-term administration of antiarrhythmic medication may be useful to demonstrate potential improvement of MR in sinus rhythm.

Indexed as

Anti-Arrhythmia AgentsAtrial FibrillationMitral Valve InsufficiencyAgedCombined Modality TherapyElectric CountershockHumansMaleTreatment OutcomeAnti-Arrhythmia AgentsFunctional mitral regurgitationHeart failureMitral valve interventionRate-controlRhythm-control

Identifiers

PMID39331145

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.